UroGen Pharma falls on wider-than-expected Q4 loss

UroGen Pharma

10/03/2025 16:41

** Nasdaq-listed shares of UroGen Pharma UR8.F, URGN.O down 4.2% at $9.41

** Co reports a quarterly net loss of 80 cents per share, compared with analysts' estimate of a loss of 72 cents, according to data compiled by LSEG

** Co posts quarterly net product revenue of bladder cancer drug, Jelmyto, at $24.6 million, up from $23.5 million a year earlier

** Co expects 2025 net product revenues from Jelmyto to be in the range of $94 to $98 million

** Up to last close, URGN has fallen 45.5% in the past 12 months

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))